

Regimen Reference Order – THOR – crizotinib

ARIA: LUNG – [crizotinib]

Planned Course: Twice daily until disease progression or unacceptable toxicity
(1 cycle = 30 days)

Indication for Use: Non-Small Cell Lung Cancer ROS-1 or ALK Positive Locally Advanced or Metastatic

Proceed with treatment if:

- **ANC equal to or greater than $1 \times 10^9/L$ AND Platelets equal to or greater than $100 \times 10^9/L$**
- **AST/ALT equal to or less than 5 times the upper limit of normal**
- **Total bilirubin equal to or less than 1.5 times the upper limit of normal**
- ❖ **Contact Physician if parameters not met**

SEQUENCE OF MEDICATION ADMINISTRATION

Treatment Regimen – THOR – crizotinib

Drug	Dose	CCMB Administration Guideline
crizotinib	250 mg	Orally twice daily with or without food Swallow whole (Self-administered at home)
crizotinib (Xalkori®) available dosage strengths: 200 mg and 250 mg capsules Classification: Cytotoxic, Hazardous		

REQUIRED MONITORING

- CBC, serum creatinine, urea, electrolytes, liver enzymes and heart rate as per Physician Orders
 - Every two weeks for the first month, then
 - At the physician's discretion but no less than every three months
- Clinical toxicity assessment including assessment in changes to vision at every clinic visit
- EKG prior to starting therapy, after 1 month of treatment and as clinically indicated

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
Not Applicable		

INSTRUCTIONS FOR PATIENTS

- Inform patient to report:
 - any new/worsening cough or shortness of breath must be reported and assessed urgently by the Oncologist/FPO because of risk of pneumonitis
 - vision loss
- crizotinib has potential for drug-drug interactions. Patients should notify clinic prior to starting any new medication
- Avoid grapefruit and grapefruit juice, Seville oranges (i.e. orange marmalade) and starfruit
- Reinforce applicable safe handling precautions of medications, blood and body fluids while on crizotinib

ADDITIONAL INFORMATION

- crizotinib can prolong QT interval and cause bradycardia
- crizotinib has been associated with hepatotoxicity, including fatal outcomes, interstitial lung disease (pneumonitis), and severe vision loss